pulmonary disorders
Lung Carcinoma
Prognosis for Lung Carcinoma
For SCLC,the overall prognosis is poor. The median survival time for limited-stage SCLC is 20 months, with a 5-year survival rate of 20%. Patients with extensive-stage SCLC do especially poorly, with a 5-year survival rate of<1%. the 5-year survival rate varies by stage, from 8 to 92% for patients with stage I disease to 0 to 10 % for patients with stage IV disease ( Prognosis reference ). On average, untreated patients with metastatic NSCLC survive 6 months, whereas the median survival for treated patients is about 9 months. Patient survival has improved in both early and later stage NSCLC. Evidence shows improved survival in early-stage disease (stages IB to IIIB) when platinum-based chemotherapy regimens are used after surgical resection. In addition, targeted therapies have improved survival in patients with stage IV disease, in particular patients with an 1.Goldstraw P, Chansky K, Crowley J, et al: The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.J Thorac Oncol11(1):39-51, 2016. doi:10.1016/j.jtho.2015.09.009 